By Connor Hart
Medtronic received approval for its OmniaSecure defibrillation lead for placement within the right ventricle, from the Food and Drug Administration.
The medical technology company said Friday that the device, with a 1.6 millimeter diameter, is the smallest defibrillation lead. It was indicated for patients ages 12 and up, including those with smaller anatomies.
The lead connects to an implantable defibrillator, or a device that applies an electric charge or current to the heart, to restore a normal heartbeat.
Medtronic said its OmniaSecure device can be used to treat potentially life-threatening conditions including ventricular tachyarrhythmias, a heart rhythm disorder where the heart's lower chambers beat too fast, and ventricular fibrillation, an arrhythmia in which the heart's ventricles quiver instead of contracting normally.
While the device was approved for use within the right ventricle, the company is studying placing the device in the left bundle branch area. This placement, which still requires FDA approval, has the potential to enable physiologic pacing to more closely mimic the heart's natural conduction system, it said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 25, 2025 18:12 ET (22:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.